文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤:CAR-T与双特异性抗体的序贯治疗系统综述与meta分析

Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.
PubMed 文献 · Lancet Haematol · 2025-12-22

该系统综述与meta分析检索MEDLINE、Embase及2024–2025年血液学会议,纳入15项临床试验和15项回顾性研究共2122例患者,间接比较双特异性抗体(BsAb)后CAR-T与CAR-T后BsAb的疗效。

核心结论

  • 基于当前证据,BsAb前置治疗可能提高后续CAR-T治疗大B细胞淋巴瘤的疗效。
  • 结论受样本量小的限制,需随机对照试验验证最佳序贯方案。

研究设计与样本

  • 系统综述与meta分析,检索MEDLINE和Embase(2010年1月1日至2025年9月16日)及2024–2025年血液学会议。
  • 纳入15项临床试验和15项回顾性研究,共2122例患者。
  • 采用逆方差随机效应meta分析对独立研究的汇总估计进行间接比较。
  • 使用Joanna Briggs Institute和MINORS清单进行偏倚评估,PROSPERO注册号CRD420251071424。

临床怎么用

  • 对于计划接受CAR-T的大B细胞淋巴瘤患者,可考虑前置BsAb治疗以改善后续CAR-T疗效。
  • CAR-T后复发患者选择BsAb时,联合治疗可能优于单药。
  • 当前证据支持设计随机对照试验以确定最佳序贯策略。

局限性

  • 结论受样本量小的限制。
  • 证据主要来自回顾性研究和单臂临床试验,存在间接比较的固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment sequence for large B-cell lymphoma is unknown. We aimed to assess through meta-analysis the comparative effectiveness of bispecific antibodies (BsAb) after chimeric antigen receptor T-cell therapy (CAR-T) or CAR-T after BsAb. METHODS: We performed a systematic review and meta-analysis by searching MEDLINE and Embase from Jan 1, 2010, until Sept 16, 2025, and haematological conferences in 2024 and 2025 for studies assessing effectiveness of BsAb monotherapy or combination therapy after CAR-T and CAR-T after BsAb. We assessed summary data from published studies and abstracts for survival endpoints, response outcomes, and adverse events (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). We performed an indirect comparison of pooled estimates from separate studies (retrospective studies and single-arm clinical trials) by an inverse variance random-effects meta-analysis. We used the Joanna Briggs Institute and Methodological Index for Non-Randomised Studies checklists for bias assessment. This study is registered with PROSPERO (CRD420251071424). FINDINGS: 2122 patients were included across 15 clinical trials and 15 retrospective studies, drawn from 14 haematology conference abstracts and 19 full text articles. Five studies represented 113 patients for CAR-T after BsAb, 20 studies represented 737 patients for BsAb after CAR-T, and five studies included BsAb combination treatments after CAR-T with 125 patients. In studies that reported demographic information (27 of 28 studies), the mean or median age ranged from 48 to 73 years. We found a pooled complete response rate for CAR-T after BsAb of 53·7% (95% CI 39·8-67·0; I2 =38·0%; four studies [n=101]) compared with 29·4% (25·1-34·0; 34·8%; 18 studies [n=680]; p=0·0008) for BsAb after CAR-T. When excluding abstracts from conferences the pooled complete response rate for BsAb after CAR-T was 28·1% (95% CI 23·3-33·4 I2 =33·3%, 12 studies [n=511]). The pooled complete response rate for BsAb combination after CAR-T was 46·4% (37·9-55·2; I2 =0·0%; five studies [n=125]) compared with 29·4% (25·1-34·0; I2 =34·8%; 18 studies [n=680]; p=0·0005) for BsAb monotherapy after CAR-T. Finally, we found an improved objective response rate in patients treated with CAR-T after BsAb compared with patients treated with CAR-T without previous BsAb exposure (pooled risk ratio of 1·62 [95% CI 1·24-2·11]; two studies [n=57, n=64]; p=0·0004). INTERPRETATION: Based on current evidence, our meta-analysis suggests that BsAb therapy before CAR-T could improve future CAR-T effectiveness for large B-cell lymphoma, although our conclusions are limited by small sample sizes. Nonetheless, our findings have important implications for the design of randomised controlled trials to identify the optimal treatment sequence of CAR-T and BsAb. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Sorin M, Okde R, Goulet M, et al. Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis. Lancet Haematol. 2025. PMID: 41448213. doi:10.1016/S2352-3026(25)00318-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。